Abstract: The present invention relates to agents comprising a binding moiety with binding specificity for SRCR domain 1 of the CD163 receptor, for use in medicine. The invention also relates to methods, uses, kits and compositions comprising such agents.
Type:
Grant
Filed:
September 29, 2010
Date of Patent:
August 8, 2017
Assignees:
AFFINICON APS, AARHUS UNIVERSITY HOSPITAL
Inventors:
Niels Jonas Heilskov Graversen, Pia Svendsen, Peter Astrup Christensen, Maciej Bogdan Maniecki, Søren Kragh Moestrup, Holger Jon Møller, Gabriele Anton
Abstract: The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).
Type:
Application
Filed:
December 30, 2008
Publication date:
July 16, 2009
Applicants:
K.U. Leuven Research and Development, Aarhus Universitet, Aarhus University Hospital
Inventors:
Greta Van Den Berghe, Steffen Thiel, Troels Krarup Hansen
Abstract: The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).
Type:
Application
Filed:
September 23, 2003
Publication date:
June 8, 2006
Applicants:
K.U. Leuven Research and Development, Aarhus University Hospital
Inventors:
Greta Van Der Berghe, Steffen Thiel, Troels Hansen